

# Timothy Rittman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7690396/publications.pdf>

Version: 2024-02-01

63  
papers

3,463  
citations

186265

28  
h-index

161849

54  
g-index

78  
all docs

78  
docs citations

78  
times ranked

5397  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adolescence is associated with genomically patterned consolidation of the hubs of the human brain connectome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9105-9110.	7.1	415
2	Transcriptional data: a new gateway to drug repositioning?. <i>Drug Discovery Today</i> , 2013, 18, 350-357.	6.4	209
3	Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. <i>Brain</i> , 2018, 141, 550-567.	7.6	190
4	Gene transcription profiles associated with inter-modular hubs and connection distance in human functional magnetic resonance imaging networks. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2016, 371, 20150362.	4.0	188
5	T1-Weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1633-1638.	3.9	158
6	Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 925-929.	1.9	135
7	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	10.2	128
8	Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. <i>Neuropharmacology</i> , 2013, 64, 490-495.	4.1	121
9	Multiple Modes of Impulsivity in Parkinson's Disease. <i>PLoS ONE</i> , 2014, 9, e85747.	2.5	116
10	Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. <i>Brain</i> , 2014, 137, 1145-1155.	7.6	113
11	Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. <i>Brain</i> , 2020, 143, 1588-1602.	7.6	113
12	The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 544-551.	1.9	94
13	Improving Response Inhibition in Parkinson's Disease with Atomoxetine. <i>Biological Psychiatry</i> , 2015, 77, 740-748.	1.3	93
14	Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson's disease. <i>Brain</i> , 2016, 139, 161-173.	7.6	88
15	Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2016, 48, 153-160.	3.1	79
16	Atomoxetine restores the response inhibition network in Parkinson's disease. <i>Brain</i> , 2016, 139, 2235-2248.	7.6	76
17	Improving response inhibition systems in frontotemporal dementia with citalopram. <i>Brain</i> , 2015, 138, 1961-1975.	7.6	71
18	In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease. <i>Science Advances</i> , 2021, 7, eabh1448.	10.3	70

#	ARTICLE	IF	CITATIONS
19	The medial frontal-prefrontal network for altered awareness and control of action in corticobasal syndrome. <i>Brain</i> , 2014, 137, 208-220.	7.6	66
20	Reorganization of cortical oscillatory dynamics underlying disinhibition in frontotemporal dementia. <i>Brain</i> , 2018, 141, 2486-2499.	7.6	64
21	Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. <i>Human Brain Mapping</i> , 2016, 37, 1026-1037.	3.6	60
22	Neurophysiological signatures of Alzheimer's disease and frontotemporal lobar degeneration: pathology versus phenotype. <i>Brain</i> , 2018, 141, 2500-2510.	7.6	60
23	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2019, 77, 169-177.	3.1	47
24	Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease. <i>Neuropsychopharmacology</i> , 2016, 41, 2171-2177.	5.4	43
25	Nutritional factors associated with survival following enteral tube feeding in patients with motor neurone disease. <i>Journal of Human Nutrition and Dietetics</i> , 2010, 23, 408-415.	2.5	41
26	Neuroinflammation predicts disease progression in progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 769-775.	1.9	40
27	Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy. <i>Annals of Neurology</i> , 2020, 88, 1194-1204.	5.3	38
28	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services" part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 169.	6.2	35
29	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	4.2	33
30	Managing cognition in progressive supranuclear palsy. <i>Neurodegenerative Disease Management</i> , 2016, 6, 499-508.	2.2	32
31	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.8	31
32	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27
33	Synaptic density in carriers of C9orf72 mutations: a [sup>11C]UCBâ€ PET study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1515-1523.	3.7	27
34	Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloidâ€positive mild cognitive impairment is associated with key clinical features. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 690-699.	2.4	26
35	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	2.4	26
36	Inâ€vivo coupling of tau pathology and cortical thinning in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 678-687.	2.4	24

#	ARTICLE	IF	CITATIONS
37	In vivo PET imaging of neuroinflammation in familial frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 319-322.	1.9	21
38	Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCBJ PET study. <i>Brain</i> , 2022, 145, 340-348.	7.6	21
39	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. <i>Brain Communications</i> , 2020, 2, .	3.3	20
40	In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies. <i>Neurobiology of Aging</i> , 2021, 101, 187-198.	3.1	17
41	Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals. <i>Psychopharmacology</i> , 2017, 234, 2289-2297.	3.1	16
42	Falls in Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 16-24.	1.5	16
43	Towards accurate and unbiased imaging-based differentiation of Parkinson's disease, progressive supranuclear palsy and corticobasal syndrome. <i>Brain Communications</i> , 2020, 2, fcaa051.	3.3	14
44	Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants. <i>Brain Communications</i> , 2021, 3, fcab206.	3.3	12
45	Progressive supranuclear palsy: diagnosis and management. <i>Practical Neurology</i> , 2021, 21, 376-383.	1.1	12
46	Neurological update: neuroimaging in dementia. <i>Journal of Neurology</i> , 2020, 267, 3429-3435.	3.6	11
47	Is referral to the neuro-oncology MDT safe?. <i>British Journal of Neurosurgery</i> , 2012, 26, 321-324.	0.8	10
48	Atomoxetine and citalopram alter brain network organization in Parkinson's disease. <i>Brain Communications</i> , 2019, 1, fcz013.	3.3	10
49	Test Your Memory (TYM) and Test Your Memory for Mild Cognitive Impairment (TYM-MCI): A Review and Update Including Results of Using the TYM Test in a General Neurology Clinic and Using a Telephone Version of the TYM Test. <i>Diagnostics</i> , 2019, 9, 116.	2.6	10
50	In Vivo <sup>18</sup> F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1052-1057.	5.0	9
51	Test Your Memory (TYM test): diagnostic evaluation of patients with non-Alzheimer dementias. <i>Journal of Neurology</i> , 2019, 266, 2546-2553.	3.6	8
52	Altered network stability in progressive supranuclear palsy. <i>Neurobiology of Aging</i> , 2021, 107, 109-117.	3.1	8
53	Altered structural connectivity networks in dementia with lewy bodies. <i>Brain Imaging and Behavior</i> , 2021, 15, 2445-2453.	2.1	8
54	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	2.7	8

#	ARTICLE	IF	CITATIONS
55	Human papillomavirus infection in women who develop high-grade cervical intraepithelial neoplasia or cervical cancer: a case-control study in the UK. <i>British Journal of Cancer</i> , 2005, 92, 1794-1799.	6.4	7
56	Prediagnostic Progressive Supranuclear Palsy - Insights from the UK Biobank. <i>Parkinsonism and Related Disorders</i> , 2022, 95, 59-64.	2.2	7
57	Co-Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1225-1233.	1.5	6
58	The basal ganglia in cognitive disorders. , 2016, , 69-80.		4
59	Exploration of functional brain networks in neurodegenerative disease. <i>Lancet, The</i> , 2013, 381, S92.	13.7	1
60	Reply: Brain oscillations, inhibition and social inappropriateness in frontotemporal degeneration. <i>Brain</i> , 2018, 141, e74-e74.	7.6	1
61	[P1-029]: IN GENETIC FRONTOTEMPORAL DEMENTIA, FUNCTIONAL NETWORK EFFICIENCY IS MAINTAINED UNTIL THE ONSET OF SYMPTOMS: EVIDENCE FOR FUNCTIONAL RESILIENCE TO STRUCTURAL CHANGE. <i>Alzheimer's and Dementia</i> , 2017, 13, P244.	0.8	0
62	[P1-415]: IN GENETIC FRONTOTEMPORAL DEMENTIA, FUNCTIONAL NETWORK EFFICIENCY IS MAINTAINED UNTIL THE ONSET OF SYMPTOMS: EVIDENCE FOR FUNCTIONAL RESILIENCE TO STRUCTURAL CHANGE. <i>Alzheimer's and Dementia</i> , 2017, 13, P436.	0.8	0
63	Trajectory of apathy, cognition and neural correlates in the decades before symptoms in frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e041821.	0.8	0